% | $
Quotes you view appear here for quick access.


  • elliottaleah elliottaleah Dec 5, 2012 4:15 PM Flag

    London news

    Does the Pluripotent cells research plans news out of London impact acts? they are not mentioned but every other drug company is.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • elliot, I still think ACTC is going to reap great advantage from continuing to develop hESC research and treatments. To be sure, they are also pursuing iPS approaches as well and have as good a chance as anyone for coming up with important innovations there. Happily, this new StemBANCC consortium indicates how important the prospects for stem cell treatments are becoming.

      Sentiment: Strong Buy

    • Does it say they're part of the consortium? NO, Here's who's involved-

      The project is a public-private partnership backed by the European Union's Innovation Medicines Initiative and is half funded by the drug industry and half by the EU.

      Other drugmakers involved are Abbott, Boehringer Ingelheim, Eli Lilly, Janssen, Merck KgaA, Novo Nordisk, Orion, Pfizer and Sanofi.